CLSA Trims HUTCHMED Target Price to HK$30.40, Keeps Outperform Rating

Stock News03-09

CLSA has adjusted its forecasts for HUTCHMED (00013), lowering its sales projections for this year and next by 21% and 16%, respectively. Net profit estimates for the same periods were reduced by 50% and 27%. The firm's target price was cut from HK$31.40 to HK$30.40, while its "Outperform" rating was maintained. HUTCHMED's 2025 results were mixed, with sales falling short of expectations due to commercial headwinds, although net profit exceeded forecasts. The report indicated that 2026 oncology business guidance suggests a commercial recovery is on the horizon, with the new ATTC pipeline expected to be a key growth driver in the coming years.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166006895?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 15:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166006895","market":"sh","top_or_hot":-1,"title":"CLSA Trims HUTCHMED Target Price to HK$30.40, Keeps Outperform Rating","media":"Stock News","content":"<p>CLSA has adjusted its forecasts for HUTCHMED (00013), lowering its sales projections for this year and next by 21% and 16%, respectively. Net profit estimates for the same periods were reduced by 50% and 27%. The firm's target price was cut from HK$31.40 to HK$30.40, while its \"Outperform\" rating was maintained. HUTCHMED's 2025 results were mixed, with sales falling short of expectations due to commercial headwinds, although net profit exceeded forecasts. The report indicated that 2026 oncology business guidance suggests a commercial recovery is on the horizon, with the new ATTC pipeline expected to be a key growth driver in the coming years.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CLSA Trims HUTCHMED Target Price to HK$30.40, Keeps Outperform Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCLSA Trims HUTCHMED Target Price to HK$30.40, Keeps Outperform Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-09 15:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CLSA has adjusted its forecasts for HUTCHMED (00013), lowering its sales projections for this year and next by 21% and 16%, respectively. Net profit estimates for the same periods were reduced by 50% and 27%. The firm's target price was cut from HK$31.40 to HK$30.40, while its \"Outperform\" rating was maintained. HUTCHMED's 2025 results were mixed, with sales falling short of expectations due to commercial headwinds, although net profit exceeded forecasts. The report indicated that 2026 oncology business guidance suggests a commercial recovery is on the horizon, with the new ATTC pipeline expected to be a key growth driver in the coming years.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1588","symbol_name":"回港中概股","start_time":0,"source_url":"","article_id":"1166006895","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166006895","pubTimestamp":1773041655,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CLSA has adjusted its forecasts for HUTCHMED (00013), lowering its sales projections for this year and next by 21% and 16%, respectively. Net profit estimates for the same periods were reduced by 50%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1588":"回港中概股","BK4588":"碎股","BK1191":"制药","BK4585":"ETF&股票定投概念","BK1587":"次新股","00013":"和黄医药","HCM":"和黄医药","BK4007":"制药","BK4531":"中概回港概念"},"translate_title":"里昂证券下调和黄医药目标价至30.40港元，维持跑赢大盘评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"HCM":1},"content_text":"CLSA has adjusted its forecasts for HUTCHMED (00013), lowering its sales projections for this year and next by 21% and 16%, respectively. Net profit estimates for the same periods were reduced by 50% and 27%. The firm's target price was cut from HK$31.40 to HK$30.40, while its \"Outperform\" rating was maintained. HUTCHMED's 2025 results were mixed, with sales falling short of expectations due to commercial headwinds, although net profit exceeded forecasts. The report indicated that 2026 oncology business guidance suggests a commercial recovery is on the horizon, with the new ATTC pipeline expected to be a key growth driver in the coming years.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166006895","isCrawlerRequest":true}